| Ytd | -11.13% | |
| 1y | 14.90% |
| Open | Prev Close | 6.71 | Low | High | Mkt Cap | 438.34M | |||
| Vol | 0.00 | Avg Vol | 285.43K | EPS | -1.05 | P/E | N/A | Forward P/E | N/A |
| Beta | 1.23 | Short Ratio | 27.74 | Inst. Own | 12.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 6.83 | 200-d Avg | 6.94 | 1yr Est | 0.00 |
EPRX News
Oppenheimer analyst Jay Olson initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a
US stock futures up, VNET Group shares down 3.8% after reporting Q1 loss of $(1.20) per share on $39
Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, COD
Top analysts changed outlook on top names. See all rating changes at benzinga.com/analyst-stock-rati
Stifel analyst Annabel Samimy initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which missed t
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX)
HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX)
HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX)
This is the first release of 36-week symptom response & tissue health data for the highest dose
William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market poten
Wall Street analysts changed outlook on top names: Morgan Stanley raised Lemonade's PT to $85,
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX)
HC Wainwright & Co. analyst Brandon Folkes maintains Eupraxia Pharmaceuticals (NASDAQ:EPRX) w
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.37) per share which missed t
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX)
Cantor Fitzgerald analyst Kristen Kluska maintains Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a
HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX)
Eupraxia Pharmaceuticals reported new trial data showing EP-104GI improved esophagus tissue health a
At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date,
The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability
Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market
Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares rose sharply during today’s pre-market